TD Cowen maintained a Buy rating on United Therapeutics (UTHR), Kept the PT Unchanged

United Therapeutics Corporation (NASDAQ:UTHR) is one of the Best Extremely Profitable Stocks to Buy Right NowOn July 15, Analyst Joseph Thome from TD Cowen maintained a Buy rating on United Therapeutics Corporation (NASDAQ:UTHR) with a price target of $400.

The analyst noted that he is optimistic about the company’s upcoming Phase III trial results for Tyvaso, which treats idiopathic pulmonary fibrosis. He believes the drug could show significant clinical benefits due to its unique mechanism and positive prior data. Thome noted the INCREASE Trial demonstrated the drug’s potential to improve lung function in IPF patients.

TD Cowen maintained a Buy rating on United Therapeutics (UTHR), Kept the PT Unchanged

A team of scientists in a laboratory, running tests on a biotechnology product.

Moreover, the analyst also appreciated United Therapeutics Corporation’s (NASDAQ:UTHR) financial performance, noting that the recent quarterly revenue exceeded expectations driven by solid sales of main products like Remodulin and Orenitram.

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and markets therapies primarily for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

While we acknowledge the potential of UTHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UTHR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.